GlaxoSmithKline Ebola Vaccine Found Safe in Early Tests
This article is for subscribers only.
GlaxoSmithKline Plc’s Ebola vaccine produced responses from the immune system and didn’t raise safety concerns in a study with 20 healthy adults, completing an initial step toward making it widely available.
The participants in the early-stage clinical trial in Maryland all produced antibodies, according to a preliminary report published yesterday in the New England Journal of Medicine. Two participants developed brief fevers within a day of vaccinations, but there were no serious adverse effects.